www.racap.com Open in urlscan Pro
40.71.11.128  Public Scan

Form analysis
0 forms found in the DOM

Text Content

RA CAPITAL

menu
 * Home
 * about us
   * About RA Capital
   * Our Team
   * What We Do
   * Social Responsibility
 * venture
   * Venture AT RA
   * Our Portfolio
   * Venture Testimonials
 * techatlas
   * TechAtlas Overview
   * Work With Us
   * map catalog
 * join us
 * knowledge
   * courses
   * Covid-19
   * perspectives
   * Innovator Resources
 * gateway
 * faq
 * contact
   * contact ra capital
   * investor login

Your browser does not support the video tag.


EVIDENCE-BASED INVESTING


IN HEALTHCARE & LIFE SCIENCES



Artist: Luke Jerram | Title: Ebola

RA CAPITAL MANAGEMENT IS A MULTI-STAGE INVESTMENT MANAGER

We are dedicated to evidence-based investing in public and private healthcare
and life science companies developing drugs, medical devices, diagnostics,
services, and research tools.

ABOUT RA CAPITAL

VENTURE INVESTING

WHY WORK WITH RA CAPITAL?

We can work with you to build a company that brings your idea from the lab into
the clinic and ultimately improves the lives of patients.

ABOUT VENTURE

RESEARCH AT RA CAPITAL

TECHATLAS MAPS PROVIDE CONTEXT AND UNDERSTANDING.

TechAtlas is a division of RA Capital that functions as an internal think tank,
analyzing scientific and clinical data from academic literature and thousands of
industry product development programs.

ABOUT TECHATLAS


OUR TEAM

Many Backgrounds. Different Perspectives. Persistently Curious.

MEET THE TEAM

MEGHAN PETROWSKI

Business Operations Manager/Recruiting Coordinator

ERIN CLUTTER

Head of Graphics

REZ HALSE, PHD

President, RAVen

PIETER BOELHOUWER

Partner and Managing Director + Strategy and Operations

ASTHA BILIMORIA

Data Analyst Associate

DANIEL BAHCHELI

Associate Director


MEGHAN PETROWSKI

Business Operations Manager/Recruiting Coordinator



Meghan Petrowski is an Business Operations Manager / Recruiting Coordinator at
RA Ventures (RAVen). Her primary responsibilities are to coordinate with all of
RAVen’s operational teams to manage and execute critical operations, implement
projects across functions, and assist in recruiting efforts for RAVen. Meghan
previously worked as an Executive Assistant at Silversmith Capital Partners and
as the Associate Athletic Director at the Academy of Art University. Meghan has
a BA in American Studies from the University of California, Berkeley and played
on the women's lacrosse team.




ERIN CLUTTER

Head of Graphics

Erin Clutter is the Head of Graphics at RA Capital Management. Erin’s primary
responsibilities at RA Capital are to manage the design and creation of all
internal and external documents and resources for the company, including
competitive landscapes of drugs and medical devices for disease indications and
capabilities, set brand standards, and oversee internal and external marketing
efforts. Erin holds a Bachelor of Fine Arts degree from the Massachusetts
College of Art & Design. She worked previously in desktop publishing and as a
freelance designer.


REZ HALSE, PHD

President, RAVen



Rez Halse is President of RAVen, also known as RA Ventures, RA Capital’s company
creation incubator. Rez’s primary responsibility is to lead early-stage private
investments in, and oversee the creation of, new companies developing
therapeutics and other medical technologies. Rez brings to RA over 20 years of
experience working in the life-science industry. Prior to RA, he served in a
dual role at Merck Research Laboratories (MRL). He was Vice President of Merck
business development and licensing where he led BD activities in the US (West
Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures
where he led equity investing in early-stage therapeutics companies. Prior to
Merck, he was a Partner with the Partners Innovation Fund, the corporate venture
arm of Mass General Brigham hospital (formerly Partners HealthCare), where he
invested in Seed/Series A therapeutics-focused companies. Rez has also held
roles at Novartis, a virtual R&D company (BVD), and Xcellsyz Ltd, a UK-based
start-up. Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle
University, UK.




PIETER BOELHOUWER

Partner and Managing Director



Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations
at RA Capital Management. Pieter’s primary responsibility at RA Capital is to
lead major strategic initiatives and drive operational excellence across the
firm. Pieter holds a BA from Trinity College and a JD from Yale Law School.
Pieter previously worked as a consultant with McKinsey & Company, where he
managed a variety of healthcare engagements, including pharmaceutical mergers,
biotech product launch plans, OTC product rationalization, and hospital
acquisitions. He held senior management positions at two successful start-up
companies that were acquired and he has over 14 years of experience investing in
the global healthcare sector, both as a Partner and Managing Director at Matrix
Capital Management and as a General Partner and Managing Director at Ayer
Capital Management, a healthcare-focused hedge fund. He also gained extensive
legislative and public policy experience early in his career as a Legislative
Aide to former United States Senator David Boren, and as a Domestic Policy
Advisor to former Vice President Al Gore. Pieter has been recognized as one of
the outstanding leaders in the U.S. through his selection as a White House
Fellow, and he currently serves on the Board of Directors of the White House
Fellows Foundation.




ASTHA BILIMORIA

Data Analyst Associate



Astha is a Data Analyst Associate at RA Capital Management. Astha’s primary
responsibility is to identify needs for process improvement in the firm's data
analytics and then both build and implement automated solutions. Astha’s
previous experience includes Research Assistant roles at Clark University and
Corbus Pharma. Astha holds a BA in Biochemistry and Molecular Biology (with a
minor in Physics) from Clark University.




DANIEL BAHCHELI

Associate Director

Daniel Bahcheli is an Associate Director at RA Capital Management. Daniel’s
primary responsibility at RA Capital is to edit and guide development of
competitive landscapes of drugs and medical devices across a range of disease
indications and capabilities. Daniel holds both a BS and MS degree in
Microbiology and Immunology from McGill University. He worked previously as an
Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon
and Publicis Life Brands International.


JOIN OUR TEAM

We welcome inquiries from people interested in joining the RA Capital team. From
time to time we may post specific open positions, but more often we will create
positions for the right people.

Join Our Team


KNOWLEDGE

PERSPECTIVES

OUR PERSPECTIVES ON INVESTING

Articles, presentations, and books with our insights into biotech, healthcare,
and investing.

VIEW PUBLICATIONS

RA CAPITAL COURSES

COURSES WE TEACH

Preparing the next generation of biotech business leaders.

VIEW COURSES

“There is so much left to discover.”

Peter Kolchinsky, PhD
Managing Partner
 * 
 * RA CAPITAL MANAGEMENT
 * 200 BERKELEY St. | 18th Floor
 * BOSTON, MA 02116 | 617.778.2500

 * About Us
 * team
 * Venture
 * techatlas
 * join us
 * courses
 * perspectives
 * Covid-19
 * faq

 * contact us
 * investor login

 * 
 * RA CAPITAL MANAGEMENT
 * 200 BERKELEY St. | 18th Floor
 * BOSTON, MA 02116 | 617.778.2500

© Copyright 2001-2022 RA Capital Management, L.P. This website is for
informational purposes only and does not constitute an offer to provide
investment advisory or other services by RA Capital Management, L.P. (“RA
Capital”). Nothing contained on the website constitutes investment advice, and
the views expressed should not be taken as advice to buy, sell, or hold any
security or as an endorsement of any security or company. In preparing the
information contained in this website, RA Capital has not taken into account the
investment needs, objectives, and financial circumstances of any particular
investor, and investments and companies referenced may not be suitable for all
investors. Any views expressed were prepared based upon information available
and believed to be reliable at the time such views were written. RA Capital
makes no guarantees as to their accuracy or completeness. All information is
subject to change and may quickly become unreliable for various reasons,
including changes in market conditions or economic circumstances. By accessing
this website, you agree not to copy, reproduce, republish, upload, post,
transmit, alter, or distribute, in any way, content or materials from this
website in any manner inconsistent with the purposes for which it is offered
without the prior written consent of RA Capital.

 * Privacy Policy

Our website uses cookies to distinguish you from other users of our website.
This helps us to provide you with a good experience when you browse our website,
and also allows us to improve our site. By continuing, you accept the use of
these cookies.

dismiss




Close
Your browser does not support the video tag.